Sangamo’s Gene Therapy Gets Pfizer Stamp Of Approval – Seeking Alpha
FierceBiotech |
Sangamo's Gene Therapy Gets Pfizer Stamp Of Approval
Seeking Alpha Sangamo's (NASDAQ:SGMO) bold claim that its hemophilia A gene therapy SB-525 could be best in class has received a boost from an early tie-up with Pfizer (NYSE:PFE). Although the project has yet to enter the clinic, Sangamo believes that it could be … Pfizer doubles down on gene therapy pipeline with $70M Sangamo buy-in Pfizer expands gene therapy effort on hemophilia, bagging rights to a Sangamo drug in a $545M deal Pfizer taps Sangamo for hemophilia gene therapy |
